Spike Protein News and Research

RSS

Designer SARS-CoV-2 RBD vaccine produces dramatically improved antibody response in preclinical trials

The importance of computational modeling in the prediction of the course of the ongoing COVID-19 pandemic, as well as evaluating multiple potential drug leads, has never been more clear. Now, a new study describes a set of designer vaccine antigens that may improve vaccine stability as well as enhance the neutralizing antibody response.

13 May 2021

Study reports new monoclonal antibodies with broad neutralizing capabilities against betacoronaviruses (including SARS-CoV-2)

In a paper published on the bioRxiv* preprint server, researchers report new monoclonal antibodies that target the S2 subunit and that have broad neutralization activity against several betacoronaviruses.

13 May 2021

Pfizer-BioNTech COVID-19 vaccine effective in patients with myeloproliferative neoplasms

Researchers in the UK have provided evidence that Pfizer-BioNTech’s coronavirus disease 2019 (COVID-19) vaccine induces effective immune responses in patients with myeloproliferative neoplasms.

13 May 2021

Scientists unveil new Ebola virus vaccine design

Scientists at Scripps Research have unveiled a new Ebola virus vaccine design, which they say has several advantages over standard vaccine approaches for Ebola and related viruses that continue to threaten global health.

13 May 2021

Inexpensive test for rapid detection of COVID-19 with 90% accuracy

A low-cost, rapid diagnostic test for COVID-19 developed by Penn Medicine provides COVID-19 results within four minutes with 90 percent accuracy.

12 May 2021

Spread of minority SARS-CoV-2 variants in New York City

Viruses mutate to survive. But not all mutations are beneficial to the virus. On the other hand, some mutations such as N501Y and E484K on the spike protein propelled specific severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants to ‘variant of concern’ status, due to their ability to increase transmission and weaken the response of neutralizing antibodies.

12 May 2021

Evolutionary-spreading model predicts another devastating COVID-19 peak around July 2021

The emergence of this variant highlighted the uneven pace of mutation and selection of variants. New bioinformatics tools are the need of the hour to clarify this and confirm a dynamic evolution by tracking the mutation rates of the spike protein. It generally takes 1 – 6 months for current variants causing COVID-19 case peaks and deaths to survive the pressure of selection.

11 May 2021

An intranasal COVID-19 vaccine elicits long-lasting immunity against SARS-CoV-2 variants in vivo

A team of scientists from the Washington University School of Medicine and the University of Texas Medical Branch, USA, has recently evaluated the durability and robustness of an adenovirus-vectored, spike-based intranasal COVID-19 vaccine in mice.

11 May 2021

Researchers design compounds that prevent SARS-CoV-2 entry in human lung cells

Researchers have designed a new class of TMPRSS2 inhibitors that have shown broad antiviral activity against coronaviruses, including the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

11 May 2021

MIT researchers generate the complete gene annotation of SARS-CoV-2 genome

In early 2020, a few months after the Covid-19 pandemic began, scientists were able to sequence the full genome of the virus that causes the infection, SARS-CoV-2. While many of its genes were already known at that point, the full complement of protein-coding genes was unresolved.

11 May 2021

The "key" to vaccine development depends on virus’ binding to human cells

New variants of the SARS-CoV-2 virus most likely will necessitate the development of more vaccine options in the years ahead, and a biomedical scientist at Iowa State University believes the "key" to that development lies in the way the virus binds to human cells.

11 May 2021

The travel-related origin and spread of SARS-CoV-2 B.1.620 strain

A new preprint research paper posted to the medRxiv* server describes a new variant B.1.620, which appeared in Lithuania, and is now prevalent in several countries in Europe, as well as in central Africa.

11 May 2021

Lab reports 1st instance of SARS-CoV-2 variants affecting antigen test performance

Researchers from the US recently determined the sensitivity of the Quidel Sofia SARS Antigen FIA test (Sofia 2). They found a high viral load specimen that tested negative repeatedly while using this antigen test. The study is published on the preprint server, medRxiv.

10 May 2021

New vaccine shows potential to protect from a variety of coronavirus infections

A potential new vaccine developed by members of the Duke Human Vaccine Institute has proven effective in protecting monkeys and mice from a variety of coronavirus infections -- including SARS-CoV-2 as well as the original SARS-CoV-1 and related bat coronaviruses that could potentially cause the next pandemic.

10 May 2021

Research suggests Pfizer-BioNTech COVID-19 vaccine reprograms innate immune responses

Researchers in The Netherlands have warned that Pfizer-BioNTech’s coronavirus disease 2019 (COVID-19) vaccine induces complex reprogramming of innate immune responses that should be considered in the development and use of mRNA-based vaccines.

10 May 2021

Preclinical study finds sex differences in neurological response to SARS-CoV-2 infection

Neurological problems during and after COVID-19 are persistent and frequent. However, research is still ongoing as to why certain people exhibit specific symptoms. Research led by Yi-Ping Hsueh from the Institute of Molecular Biology in Taiwan suggests SARS-CoV-2 infection in the brain could be sex-dependent.

10 May 2021

Combo COVID-flu vaccine protects against current and emerging variants in animal model

Now, in new research posted to the bioRxiv preprint server, scientists at Novavax, Inc. present a vaccine including recombinant influenza hemagglutinin (HA) antigen along with recombinant SARS-CoV-2 spike protein, with saponin Matrix-M adjuvant. Both have passed independent safety tests in phase 1 trials.

10 May 2021

How did SARS-CoV-2 first evolve in humans?

In a perspective article recently published in the journal Science, Hyeryun Choe and Michael Farzan from the Scripps Research Institute, USA, have described the early-stage evolution of SARS-CoV-2 in humans. They have provided a detailed overview of how early mutations in SARS-CoV-2 spike protein facilitate its adaptation in human systems.

7 May 2021

Immunosuppression in COVID-19 promotes emergence of multiple immune escape mutants

An interesting new study describes the emergence of several such variants from a chronically immunosuppressed COVID-19 patient, who remained infected for over 170 days before clearing the virus.

7 May 2021

The ancestor of SARS-CoV-2’s Wuhan strain was circulating in late October 2019

The SARS-CoV-2 was first reported in a case from Wuhan, China, in December 2021, and subsequently became the cause of the COVID-19 pandemic that is ravaging the world today. A new study in the journal Molecular Biology and Evolution tracks its variants all over the world since the onset of the pandemic.

7 May 2021

Spike Protein News and Research

Designer SARS-CoV-2 RBD vaccine produces dramatically improved antibody response in preclinical trials

Study reports new monoclonal antibodies with broad neutralizing capabilities against betacoronaviruses (including SARS-CoV-2)

Pfizer-BioNTech COVID-19 vaccine effective in patients with myeloproliferative neoplasms

Scientists unveil new Ebola virus vaccine design

Inexpensive test for rapid detection of COVID-19 with 90% accuracy

Spread of minority SARS-CoV-2 variants in New York City

Evolutionary-spreading model predicts another devastating COVID-19 peak around July 2021

An intranasal COVID-19 vaccine elicits long-lasting immunity against SARS-CoV-2 variants in vivo

Researchers design compounds that prevent SARS-CoV-2 entry in human lung cells

MIT researchers generate the complete gene annotation of SARS-CoV-2 genome

The "key" to vaccine development depends on virus’ binding to human cells

The travel-related origin and spread of SARS-CoV-2 B.1.620 strain

Lab reports 1st instance of SARS-CoV-2 variants affecting antigen test performance

New vaccine shows potential to protect from a variety of coronavirus infections

Research suggests Pfizer-BioNTech COVID-19 vaccine reprograms innate immune responses

Preclinical study finds sex differences in neurological response to SARS-CoV-2 infection

Combo COVID-flu vaccine protects against current and emerging variants in animal model

How did SARS-CoV-2 first evolve in humans?

Immunosuppression in COVID-19 promotes emergence of multiple immune escape mutants

The ancestor of SARS-CoV-2’s Wuhan strain was circulating in late October 2019

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News